Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p37
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 37/381)
Character Range: 11730838–11740987

Sleep prior to the MSLT must be at least 6 hours in duration.
                                                                                                                                                                    The authority application must be made in writing and must include the following
                                                                                                                                                                    (a) a completed authority prescription form; and
                                                                                                                                                                    (b) a completed Narcolepsy Initial PBS authority application and Supporting information form; and
                                                                                                                                                                    (c) details of the contraindication or intolerance to dexamfetamine sulfate; and
                                                                                                                                                                    (d) either
                                                                                                                                                                    (i) the result and date of the polysomnography test and Multiple Sleep Latency Test (MSLT) conducted by, or under the supervision of, a qualified sleep medicine practitioner; or
                                                                                                                                                                    (ii) the result and date of the electroencephalograph (EEG), conducted by, or under the supervision of, a neurologist.
                                                                                                                                                                    The polysomnography, MSLT or EEG test reports must be provided with the authority application.
C10971              P10971         CN10971          Methoxsalen                                                                                                     Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Compliance with Authority Required procedures - Streamlined Authority Code 10971
                                                                                                                                                                    Initial treatment
                                                                                                                                                                    Patient must have experienced disease progression while on at least one systemic treatment for this PBS indication prior to initiating treatment with this drug; or
                                                                                                                                                                    Patient must have experienced an intolerance necessitating permanent treatment withdrawal to at least one systemic treatment for this PBS indication prior to initiating treatment with this drug; AND
                                                                                                                                                                    The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; or
                                                                                                                                                                    The treatment must be in combination with peginterferon alfa-2a only if used in combination with another drug; AND
                                                                                                                                                                    Patient must be receiving the medical service as described in item 14247 of the Medicare Benefits Schedule; AND
                                                                                                                                                                    Patient must not have previously received PBS-subsidised treatment with this drug for this PBS indication; AND
                                                                                                                                                                    Must be treated by a haematologist; or
                                                                                                                                                                    Must be treated by a medical physician working under the supervision of a haematologist;
                                                                                                                                                                    Patient must be aged 18 years or over.
C10972              P10972         CN10972          Atezolizumab                                                                                                    Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures - Streamlined Authority Code 10972
                                                                                                                                                                    Continuing treatment where bevacizumab is discontinued - 4 weekly treatment regimen
                                                                                                                                                                    Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
                                                                                                                                                                    Patient must not have developed disease progression while being treated with this drug for this condition.
                                                                                                                                                                    PBS supply of this drug must be through only one of the two continuing treatment regimens at any given time
C10985              P10985         CN10985          Methoxsalen                                                                                                     Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Compliance with Authority Required procedures - Streamlined Authority Code 10985
                                                                                                                                                                    Initial treatment
                                                                                                                                                                    Patient must have experienced disease progression while on at least one systemic treatment for this PBS indication prior to initiating treatment with this drug; or
                                                                                                                                                                    Patient must have experienced an intolerance necessitating permanent treatment withdrawal to at least one systemic treatment for this PBS indication prior